A new study finds an increased risk of prostate cancer in men taking medications that have also been suggested to cause strokes, heart attacks and other serious cardiovascular side effects in hundreds of testosterone lawsuit claims.

The research was led by a team at the University of Illinois in Chicago, who conducted multiple experiments on male rats who received slow-release and standard testosterone implants.  Here’s what they found: between 10 and 18 percent of male rats implanted with slow-release testosterone implants developed prostate tumors, as did 50 and 71 percent of those who received standard treatments.

Leaders of the study, which was published in the journal Endocrinology, began to investigate hormone-raising medications similar to AndroGel, Testim and Axiron after determining that there was little information proving their safety and effectiveness in treating men not suffering from hypogonadism, a condition referring to abnormally-low levels of testosterone caused by an injury or disease.

FDA Experts Vote to Change Labeling on Testosterone Treatments

“The potential of testosterone treatments to increase risk of prostate cancer, an androgen dependent malignancy, has been raised repeatedly. … Conclusive data on its safety for the prostate are lacking, probably in part because large scale testosterone therapy is a recent phenomenon and prostate cancer is a notoriously slow developing disease.”

These testosterone medications, along with several others, are only approved for hypogonadism by the U.S. Food and Drug Administration (FDA), but are frequently prescribed to treat low libido, sexual dysfunction and other symptoms commonly associated with aging. This problems fall under the umbrella of “Low T,” a condition marketed by drug manufacturers  Testosterone lawsuits now filed in the U.S. accuse the makers of AndroGel and other products of promoting them for off-label uses.

A panel of expert advisers voted unanimously on September 17th to adjust labeling on these medications to clearly state the lack of evidence proving their effectiveness for uses not cleared by the FDA. “Low T” drug manufacturers should also be required to conduct studies that look into the possible heart problems associated with their products, given the findings of research that suggests an increased risk of heart attacks and strokes. In January 2014, the federal agency issued a public health alert after becoming aware of research published that previous November that found an increased risk of testosterone heart injuries.

Considering a Testosterone Lawsuit? Contact Us.

Our testosterone lawyers are standing by to answer any questions you have regarding the mounting litigation involving AndroGel, Testim, Axiron and other products. Call our Firm today to start the process of filing a lawsuit: (877) 779-1414.

Published October 21, 2014 by